The combination of CGM097, an MDM2 inhibitor, and OTX015, a bromodomain inhibitor, has led to the activation of p53 and decreased expression of MYC proteins, resulting in neuroblastoma cell death.174. This evidence concerns the gene MYC and neuroblastoma.